Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Nimotuzumab: beyond the EGFR signaling cascade inhibition.

Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T.

Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Review.

2.

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.

Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R.

Cancer Biol Ther. 2011 Feb 15;11(4):373-82. Epub 2011 Feb 15.

PMID:
21150278
3.

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.

Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T.

Cancer Biol Ther. 2010 Mar 1;9(5):343-9. Epub 2010 Mar 20.

PMID:
20448462
4.

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J.

Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6.

5.

Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.

Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, Castillo MR, Longchong M, Iznaga N, Lage A.

MEDICC Rev. 2009 Jul;11(3):27-33.

6.

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.

Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R, Lage A.

J Immunother. 2003 Mar-Apr;26(2):139-48.

PMID:
12616105
7.

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.

Crombet T, Torres O, Rodríguez V, Menéndez A, Stevenson A, Ramos M, Torres F, Figueredo R, Veitía I, Iznaga N, Pérez R, Lage A.

Hybridoma. 2001 Apr;20(2):131-6.

PMID:
11394532
8.

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.

Crombet T, Torres O, Neninger E, Catalá M, Rodríguez N, Ramos M, Fernández E, Iznaga N, Pérez R, Lage A.

Cancer Biother Radiopharm. 2001 Feb;16(1):93-102.

PMID:
11279803
9.

Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme.

Deuñas L, Alcantud V, Alvarez F, Arteaga J, Benítez A, Bopuza M, Carniege L, Cartaya B, Comas C, Cotayo R, Escobar H, Fernández H, Fernández M, Fernández R, García M, Iznaga N, la O F, Márquez J, Nordet D, Pérez J, Quintero J, Redonavich A, Robeleco M, Rodríguez H, Strander H, et al.

J Laryngol Otol. 1997 Feb;111(2):134-40.

PMID:
9102438
10.

Amplified ELISA to detect autoantibodies to N-glycolyl-GM3 ganglioside.

Iznaga N, Carr A, Fernández LE, Solozabal J, Núñez G, Perdomo Y, Morales A.

J Clin Lab Immunol. 1996;48(2):75-85.

PMID:
16296265
11.

A personal computer-based system for parallel line analysis of bioassay data.

Iznaga N, Núñez G, Solozabal J, Morales A, Artaza E, Rubio R, Cardenas E.

Comput Methods Programs Biomed. 1995 Jul;47(2):167-75.

PMID:
7587163

Supplemental Content

Loading ...
Support Center